Four-Gene Pan-African Blood Signature Predicts Progre

American Journal of Respiratory and Critical Care Medicine
197, 1198-1208
DOI: 10.1164/rccm.201711-2340oc

Citation Report

#	Article	IF	Citations
1	Research and development of new tuberculosis vaccines: a review. F1000Research, 2018, 7, 1732.	1.6	38
2	Diagnosis of HIV-associated tuberculosis. Current Opinion in HIV and AIDS, 2018, 13, 462-468.	3.8	6
3	Metabolite changes in blood predict the onset of tuberculosis. Nature Communications, 2018, 9, 5208.	12.8	129
5	Can we predict tuberculosis cure? What tools are available?. European Respiratory Journal, 2018, 52, 1801089.	6.7	73
6	Systems approaches to correlates of protection and progression to TB disease. Seminars in Immunology, 2018, 39, 81-87.	5.6	14
8	The value of transcriptomics in advancing knowledge of the immune response and diagnosis in tuberculosis. Nature Immunology, 2018, 19, 1159-1168.	14.5	88
9	Pathogen-based precision medicine for drug-resistant tuberculosis. PLoS Pathogens, 2018, 14, e1007297.	4.7	43
10	Genetic Resistance to Mycobacterium tuberculosis Infection and Disease. Frontiers in Immunology, 2018, 9, 2219.	4.8	29
11	Addressing diversity in tuberculosis using multidimensional approaches. Journal of Internal Medicine, 2018, 284, 116-124.	6.0	6
12	Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination. Seminars in Immunology, 2018, 39, 88-101.	5.6	52
13	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. European Respiratory Journal, 2018, 52, 1800946.	6.7	27
15	Where is tuberculosis transmission happening? Insights from the literature, new tools to study transmission and implications for the elimination of tuberculosis. Respirology, 2018, 23, 807-817.	2.3	17
16	Latent tuberculosis infection: Opportunities and challenges. Respirology, 2018, 23, 893-900.	2.3	63
17	Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy. Scientific Reports, 2019, 9, 11126.	3.3	13
18	The Mycobacterial HBHA Protein: A Promising Biomarker for Tuberculosis. Current Medicinal Chemistry, 2019, 26, 2051-2060.	2.4	14
19	Predicting bacterial infection outcomes using single cell RNA-sequencing analysis of human immune cells. Nature Communications, 2019, 10, 3266.	12.8	62
20	Tuberculosis Progression Does Not Necessarily Equate with a Failure of Immune Control. Microorganisms, 2019, 7, 185.	3.6	0
21	A rapid triage test for active pulmonary tuberculosis in adult patients with persistent cough. Science Translational Medicine, 2019, 11, .	12.4	44

#	Article	IF	Citations
22	Tuberculosis Vaccine Development: Progress in Clinical Evaluation. Clinical Microbiology Reviews, 2019, 33, .	13.6	70
23	Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. Frontiers in Microbiology, 2019, 10, 1441.	3.5	46
24	Predicting progression to active tuberculosis: A rate-limiting step on the path to elimination. PLoS Medicine, 2019, 16, e1002814.	8.4	8
25	Performance of host blood transcriptomic signatures for diagnosing and predicting progression to tuberculosis disease in HIV-negative adults and adolescents: a systematic review protocol. BMJ Open, 2019, 9, e026612.	1.9	7
26	Host-response-based gene signatures for tuberculosis diagnosis: A systematic comparison of 16 signatures. PLoS Medicine, 2019, 16, e1002786.	8.4	137
27	Update in Lung Infections and Tuberculosis 2018. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 414-422.	5.6	1
28	Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study. PLoS Medicine, 2019, 16, e1002781.	8.4	72
29	Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome. Frontiers in Immunology, 2019, 10, 527.	4.8	40
30	Designing tuberculosis vaccine efficacy trials â€“ lessons from recent studies. Expert Review of Vaccines, 2019, 18, 423-432.	4.4	20
31	Blood Transcriptomic Stratification of Short-term Risk in Contacts of Tuberculosis. Clinical Infectious Diseases, 2020, 70, 731-737.	5.8	66
32	Host Transcriptomics as a Tool to Identify Diagnostic and Mechanistic Immune Signatures of Tuberculosis. Frontiers in Immunology, 2019, 10, 221.	4.8	31
33	Biomarkers for tuberculosis: the case for lipoarabinomannan. ERJ Open Research, 2019, 5, 00115-2018.	2.6	47
34	Latent tuberculosis infection: diagnostic tests and when to treat. Lancet Infectious Diseases, The, 2019, 19, 231-233.	9.1	15
35	Indoleamine 2, 3-Dioxygenase-Mediated Tryptophan Catabolism: A Leading Star or Supporting Act in the Tuberculosis and HIV Pas-de-Deux?. Frontiers in Cellular and Infection Microbiology, 2019, 9, 372.	3.9	14
36	Diagnostic Tests for Latent Tuberculosis Infection. Clinics in Chest Medicine, 2019, 40, 829-837.	2.1	42
37	Transcriptional Profiling of Human Peripheral Blood Mononuclear Cells Identifies Diagnostic Biomarkers That Distinguish Active and Latent Tuberculosis. Frontiers in Immunology, 2019, 10, 2948.	4.8	32
38	Paradigm changing evidence that alter tuberculosis perception and detection: Focus on latency. Infection, Genetics and Evolution, 2019, 72, 78-85.	2.3	4
39	Advances in multiplex nucleic acid diagnostics for blood-borne pathogens: promises and pitfalls - an update. Expert Review of Molecular Diagnostics, 2019, 19, 15-25.	3.1	6

#	Article	IF	Citations
40	Current approaches toward identifying a correlate of immune protection from tuberculosis. Expert Review of Vaccines, 2019, 18, 43-59.	4.4	18
41	Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 564-571.	5.6	20
42	Tuberculosis Elimination, Research, and Respect for Persons. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 560-563.	5.6	7
43	Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virusâ€“1. Clinical Infectious Diseases, 2019, 69, 295-305.	5.8	10
44	Changes in Transcript, Metabolite, and Antibody Reactivity During the Early Protective Immune Response in Humans to Mycobacterium tuberculosis Infection. Clinical Infectious Diseases, 2020, 71, 30-40.	5.8	19
45	Host-Directed Therapy as a Novel Treatment Strategy to Overcome Tuberculosis: Targeting Immune Modulation. Antibiotics, 2020, 9, 21.	3.7	28
46	Two Clinical Prediction Tools to Improve Tuberculosis Contact Investigation. Clinical Infectious Diseases, 2020, 71, e338-e350.	5.8	9
47	Cross-validation of existing signatures and derivation of a novel 29-gene transcriptomic signature predictive of progression to TB in a Brazilian cohort of household contacts of pulmonary TB. Tuberculosis, 2020, 120, 101898.	1.9	20
48	Quantitative IFN-Î³ Release Assay and Tuberculin Skin Test Results to Predict Incident Tuberculosis. A Prospective Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 984-991.	5.6	29
50	Candida coinfection among patients with pulmonary tuberculosis in Asia and Africa; A systematic review and meta-analysis of cross-sectional studies. Microbial Pathogenesis, 2020, 139, 103898.	2.9	9
51	Tuberculosis-Associated MicroRNAs: From Pathogenesis to Disease Biomarkers. Cells, 2020, 9, 2160.	4.1	47
52	HIV and the tuberculosis â€œset pointâ€• how HIV impairs alveolar macrophage responses to tuberculosis and sets the stage for progressive disease. Retrovirology, 2020, 17, 32.	2.0	10
53	Clinical variables and gene signatures in tuberculosis. Lancet Infectious Diseases, The, 2020, 20, 1227-1229.	9.1	0
54	Blood RNA signatures predict recent tuberculosis exposure in mice, macaques and humans. Scientific Reports, 2020, 10, 16873.	3.3	4
55	An RNA-seq Based Machine Learning Approach Identifies Latent Tuberculosis Patients With an Active Tuberculosis Profile. Frontiers in Immunology, 2020, 11, 1470.	4.8	25
56	A blood RNA transcript signature for TB exposure in household contacts. BMC Infectious Diseases, 2020, 20, 403.	2.9	10
57	Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis. Seminars in Immunology, 2020, 50, 101431.	5.6	57
58	Diagnostic accuracy of plasma kynurenine/tryptophan ratio, measured by enzyme-linked immunosorbent assay, for pulmonary tuberculosis. International Journal of Infectious Diseases, 2020, 99, 441-448.	3.3	12

#	Article	IF	Citations
59	Perspective for Precision Medicine for Tuberculosis. Frontiers in Immunology, 2020, 11, 566608.	4.8	35
60	Performance of diagnostic and predictive host blood transcriptomic signatures for Tuberculosis disease: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0237574.	2.5	39
61	Distinct Features of Human Myeloid Cell Cytokine Response Profiles Identify Neutrophil Activation by Cytokines as a Prognostic Feature during Tuberculosis and Cancer. Journal of Immunology, 2020, 204, 3389-3399.	0.8	4
62	Combination of mean spot sizes of ESAT-6 spot-forming cells and modified tuberculosis-specific antigen/phytohemagglutinin ratio of T-SPOT.TB assay in distinguishing between active tuberculosis and latent tuberculosis infection. Journal of Infection, 2020, 81, 81-89.	3.3	11
63	Impact of Intermediate Hyperglycemia and Diabetes on Immune Dysfunction in Tuberculosis. Clinical Infectious Diseases, 2021, 72, 69-78.	5.8	26
64	A combination of iron metabolism indexes and tuberculosis-specific antigen/phytohemagglutinin ratio for distinguishing active tuberculosis from latent tuberculosis infection. International Journal of Infectious Diseases, 2020, 97, 190-196.	3.3	16
65	Screening for candidate biomarkers of TB in stimulated blood: another step in the quest for a test?. Thorax, 2020, 75, 534-535.	5.6	0
66	Vaccination Against Tuberculosis: Revamping BCG by Molecular Genetics Guided by Immunology. Frontiers in Immunology, 2020, 11, 316.	4.8	59
67	Blood transcriptional biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective, observational, diagnostic accuracy study. Lancet Respiratory Medicine,the, 2020, 8, 407-419.	10.7	86
68	Advances in the diagnosis and treatment of latent tuberculosis infection. Current Opinion in Infectious Diseases, 2020, 33, 166-172.	3.1	12
69	Clinical Development of New TB Vaccines: Recent Advances and Next Steps. Frontiers in Microbiology, 2019, 10, 3154.	3.5	56
70	Advancing new diagnostic tests for latent tuberculosis infection due to multidrug-resistant strains of Mycobacterium tuberculosis â€" End of the road?. International Journal of Infectious Diseases, 2020, 92, S69-S71.	3.3	12
71	Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. Lancet Respiratory Medicine,the, 2020, 8, 395-406.	10.7	128
72	Latent Tuberculosis Infectionâ€"associated Immunodiagnostic Test Responses as Biomarkers of Incipient Tuberculosis: Fruitful or Futile?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 895-898.	5.6	3
73	The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection. Frontiers in Immunology, 2020, 11, 669.	4.8	12
74	Peripheral Blood Mucosal-Associated Invariant T Cells in Tuberculosis Patients and Healthy Mycobacterium tuberculosis-Exposed Controls. Journal of Infectious Diseases, 2020, 222, 995-1007.	4.0	19
75	A transcriptional blood signature distinguishes early tuberculosis disease from latent tuberculosis infection and uninfected individuals in a Vietnamese cohort. Journal of Infection, 2020, 81, 72-80.	3.3	16
76	Ultra-low Dose Aerosol Infection of Mice with Mycobacterium tuberculosis More Closely Models Human Tuberculosis. Cell Host and Microbe, 2021, 29, 68-82.e5.	11.0	62

#	Article	IF	Citations
77	Mycobacterium tuberculosis complex and human coadaptation: a two-way street complicating host susceptibility to TB. Human Molecular Genetics, 2021, 30, R146-R153.	2.9	3
78	Tuberculosis comorbidity with rheumatoid arthritis: Gene signatures, associated biomarkers, and screening. IUBMB Life, 2021, 73, 26-39.	3.4	6
79	Tuberculous Meningitis: Pathogenesis, Immune Responses, Diagnostic Challenges, and the Potential of Biomarker-Based Approaches. Journal of Clinical Microbiology, 2021, 59, .	3.9	29
80	Comparing tuberculosis gene signatures in malnourished individuals using the TBSignatureProfiler. BMC Infectious Diseases, 2021, 21, 106.	2.9	10
83	Transcriptional signatures of human peripheral blood mononuclear cells can identify the risk of tuberculosis progression from latent infection among individuals with silicosis. Emerging Microbes and Infections, 2021, 10, 1536-1544.	6.5	4
84	Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. European Respiratory Journal, 2021, 58, 2003492.	6.7	27
85	Inflammatory Determinants of Differential Tuberculosis Risk in Pre-Adolescent Children and Young Adults. Frontiers in Immunology, 2021, 12, 639965.	4.8	7
86	Identification of Reduced Host Transcriptomic Signatures for Tuberculosis Disease and Digital PCR-Based Validation and Quantification. Frontiers in Immunology, 2021, 12, 637164.	4.8	25
87	Blood-based host biomarker diagnostics in active case finding for pulmonary tuberculosis: A diagnostic case-control study. EClinicalMedicine, 2021, 33, 100776.	7.1	26
88	Host transcriptional response to TB preventive therapy differentiates two sub-groups of IGRA-positive individuals. Tuberculosis, 2021, 127, 102033.	1.9	14
89	Use of a Contained Mycobacterium tuberculosis Mouse Infection Model to Predict Active Disease and Containment in Humans. Journal of Infectious Diseases, 2022, 225, 1832-1840.	4.0	4
90	BCGâ€induced protection against Mycobacterium tuberculosis infection: Evidence, mechanisms, and implications for nextâ€generation vaccines. Immunological Reviews, 2021, 301, 122-144.	6.0	26
91	Expression studies of tuberculosis susceptibility genes. Russian Journal of Infection and Immunity, 2021, 11, 209-222.	0.7	0
93	Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR. Frontiers in Immunology, 2020, 11, 612564.	4.8	16
94	Immune Subtyping in Latent Tuberculosis. Frontiers in Immunology, 2021, 12, 595746.	4.8	8
95	Blood RNA signature RISK4LEP predicts leprosy years before clinical onset. EBioMedicine, 2021, 68, 103379.	6.1	29
96	Lymphocyte-Related Immunological Indicators for Stratifying Mycobacterium tuberculosis Infection. Frontiers in Immunology, 2021, 12, 658843.	4.8	10
97	Combination of Blood Routine Examination and T-SPOT.TB Assay for Distinguishing Between Active Tuberculosis and Latent Tuberculosis Infection. Frontiers in Cellular and Infection Microbiology, 2021, 11, 575650.	3.9	8

#	Article	IF	Citations
98	The Evaluation and Validation of Blood-Derived Novel Biomarkers for Precise and Rapid Diagnosis of Tuberculosis in Areas With High-TB Burden. Frontiers in Microbiology, 2021, 12, 650567.	3.5	9
99	Reduced thyroxine production in young household contacts of tuberculosis patients increases active tuberculosis disease risk. JCI Insight, 2021, 6, .	5.0	5
101	Gene Set Enrichment Analysis Reveals Individual Variability in Host Responses in Tuberculosis Patients. Frontiers in Immunology, 2021, 12, 694680.	4.8	5
102	Blood transcriptomics reveal the evolution and resolution of the immune response in tuberculosis. Journal of Experimental Medicine, 2021, 218, .	8.5	36
103	A Mycobacterium tuberculosis Specific IgG3 Signature of Recurrent Tuberculosis. Frontiers in Immunology, 2021, 12, 729186.	4.8	8
105	The Tuberculosis Vaccine Development Pipeline: Present and Future Priorities and Challenges for Research and Innovation. , 2021, , 395-405.		4
106	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Scientific Reports, 2020, 10, 8629.	3.3	90
107	Whole blood mRNA expression-based targets to discriminate active tuberculosis from latent infection and other pulmonary diseases. Scientific Reports, 2020, 10, 22072.	3.3	10
113	Aetiopathogenesis, immunology and microbiology of tuberculosis. , 0, , 62-82.		1
114	What next? Basic research, new treatments and a patient-centred approach in controlling tuberculosis. , 0, , 414-429.		1
115	Research and development of new tuberculosis vaccines: a review. F1000Research, 2018, 7, 1732.	1.6	27
116	Latent tuberculosis infection: recent progress and challenges in South Korea. Korean Journal of Internal Medicine, 2020, 35, 269-275.	1.7	14
117	Overcoming the impacts of two-step batch effect correction on gene expression estimation and inference. Biostatistics, 2023, 24, 635-652.	1.5	11
118	Transcriptomic Biomarkers for Tuberculosis: Validation of NPC2 as a Single mRNA Biomarker to Diagnose TB, Predict Disease Progression, and Monitor Treatment Response. Cells, 2021, 10, 2704.	4.1	3
119	A 10-gene biosignature of tuberculosis treatment monitoring and treatment outcome prediction. Tuberculosis, 2021, 131, 102138.	1.9	10
120	Overview of the HIV-Associated Tuberculosis Epidemic. , 2019, , 1-7.		0
123	Host and Bacterial Iron Homeostasis, an Underexplored Area in Tuberculosis Biomarker Research. Frontiers in Immunology, 2021, 12, 742059.	4.8	8
124	The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study. BMC Medicine, 2021, 19, 252.	5.5	4

#	Article	IF	Citations
125	BCG and Novel Tuberculosis Vaccine Candidates in the Context of Immunodeficiencies. , 2020, , 51-62.		0
126	BCG and Novel Tuberculosis Vaccine Candidates in the Context of Immunodeficiencies. , 2020, , 1-12.		0
128	A Robust Host-Response-Based Signature Distinguishes Bacterial and Viral Infections Across Diverse Global Populations. SSRN Electronic Journal, 0, , .	0.4	2
129	Plasma host protein biomarkers correlating with increasing Mycobacterium tuberculosis infection activity prior to tuberculosis diagnosis in people living with HIV. EBioMedicine, 2022, 75, 103787.	6.1	12
130	Development and validation of a parsimonious TB gene signature using the digital NanoString nCounter platform. Clinical Infectious Diseases, 2022, , .	5.8	2
132	Framing the detection of incipient tuberculosis infection: AÂqualitative study of political prioritisation. Tropical Medicine and International Health, 2022, 27, 445-453.	2.3	1
133	Contribution and Future of High-Throughput Transcriptomics in Battling Tuberculosis. Frontiers in Microbiology, 2022, 13, 835620.	3.5	3
135	Diagnostic Advances in Childhood Tuberculosisâ€"Improving Specimen Collection and Yield of Microbiological Diagnosis for Intrathoracic Tuberculosis. Pathogens, 2022, 11, 389.	2.8	14
136	Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. Communications Medicine, 2022, 2, .	4.2	15
137	It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity. Frontiers in Immunology, 2022, 13, 840225.	4.8	19
138	Point-of-care diagnostic tests for tuberculosis disease. Science Translational Medicine, 2022, 14, eabj4124.	12.4	18
140	Latent Tuberculosis Infection Diagnosis among Household Contacts in a High Tuberculosis-Burden Area: a Comparison between Transcript Signature and Interferon Gamma Release Assay. Microbiology Spectrum, 2022, 10, e0244521.	3.0	4
141	The Association between Circulating microRNAs and the Risk of Active Disease Development from Latent Tuberculosis Infection: a Nested Case-Control Study. Microbiology Spectrum, 2022, 10, e0262521.	3.0	4
166	Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition. PLoS ONE, 2022, 17, e0267729.	2.5	2
168	Immunopathogenic overlap between COVID-19 and tuberculosis identified from transcriptomic meta-analysis and human macrophage infection. IScience, 2022, 25, 104464.	4.1	19
169	A systematic review on Correlates of Risk of TB disease in children and adults. Indian Journal of Tuberculosis, 2022, , .	0.7	0
170	Isoniazid preventive therapy and TB transcriptional signatures in people with HIV. Aids, 0, Publish Ahead of Print, .	2.2	0
172	End-point definition and trial design to advance tuberculosis vaccine development. European Respiratory Review, 2022, 31, 220044.	7.1	7

#	Article	IF	Citations
173	Transcriptional profiles predict treatment outcome in patients with tuberculosis and diabetes at diagnosis and at two weeks after initiation of anti-tuberculosis treatment. EBioMedicine, 2022, 82, 104173.	6.1	5
174	Are mRNA based transcriptomic signatures ready for diagnosing tuberculosis in the clinic? - A review of evidence and the technological landscape. EBioMedicine, 2022, 82, 104174.	6.1	11
176	Malnutrition leads to increased inflammation and expression of tuberculosis risk signatures in recently exposed household contacts of pulmonary tuberculosis. Frontiers in Immunology, 0, 13, .	4.8	7
177	Gene expression profiling identifies candidate biomarkers for new latent tuberculosis infections. A cohort study. PLoS ONE, 2022, 17, e0274257.	2.5	1
178	System-wide identification of myeloid markers of TB disease and HIV-induced reactivation in the macaque model of Mtb infection and Mtb/SIV co-infection. Frontiers in Immunology, 0, 13, .	4.8	4
179	T-cell deficiency and hyperinflammatory monocyte responses associate with Mycobacterium avium complex lung disease. Frontiers in Immunology, 0, 13, .	4.8	5
180	Advances in Diagnosis of Latent TB Infection: What Is the Latest Approach to Diagnose Latent TB Infection to Prevent TB?. Respiratory Disease Series, 2022, , 185-216.	0.0	0
182	Utility of a three-gene transcriptomic signature in the diagnosis of tuberculosis in a low-endemic hospital setting. Infectious Diseases, 2023, 55, 44-54.	2.8	1
183	Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses. PLoS ONE, 2022, 17, e0276505.	2.5	1
185	Plasma host protein signatures correlating with Mycobacterium tuberculosis activity prior to and during antituberculosis treatment. Scientific Reports, 2022, 12, .	3.3	3
186	Metabolites enhance innate resistance to human Mycobacterium tuberculosis infection. JCI Insight, 2022, 7, .	5.0	0
187	A protein signature associated with active tuberculosis identified by plasma profiling and network-based analysis. IScience, 2022, 25, 105652.	4.1	5
188	A robust host-response-based signature distinguishes bacterial and viral infections across diverse global populations. Cell Reports Medicine, 2022, 3, 100842.	6.5	6
189	Neutrophil degranulation, NETosis and platelet degranulation pathway genes are co-induced in whole blood up to six months before tuberculosis diagnosis. PLoS ONE, 2022, 17, e0278295.	2.5	4
190	Immune cell interactions in tuberculosis. Cell, 2022, 185, 4682-4702.	28.9	39
191	T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection. Nature Medicine, 2023, 29, 258-269.	30.7	23
192	Host blood-based biosignatures for subclinical TB and incipient TB: A prospective study of adult TB household contacts in Southern India. Frontiers in Immunology, 0, 13, .	4.8	1
193	Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis. EClinicalMedicine, 2023, 56, 101815.	7.1	12

#	Article	IF	Citations
194	QuantiFERON Supernatant-Based Host Biomarkers Predicting Progression to Active Tuberculosis Disease Among Household Contacts of Tuberculosis Patients. Clinical Infectious Diseases, 2023, 76, 1802-1813.	5.8	3
196	Systematic review of diagnostic and prognostic host blood transcriptomic signatures of tuberculosis disease in people living with HIV. Gates Open Research, 0, 7, 27.	1.1	0
197	Host Blood Transcriptional Signatures as Candidate Biomarkers for Predicting Progression to Active Tuberculosis. Tuberculosis and Respiratory Diseases, 2023, 86, 94-101.	1.8	2
198	Functions of exosomal non-coding RNAs to the infection with Mycobacterium tuberculosis. Frontiers in Immunology, 0, 14, .	4.8	2
199	Determinants of QuantiFERON Plus-diagnosed tuberculosis infection in adult Ugandan TB contacts: A cross-sectional study. PLoS ONE, 2023, 18, e0281559.	2.5	0
200	Correlates of Protection from Tuberculosis. , 2023, , 99-137.		0
201	Predicting Pediatric TB: The Need for Age-specific Host Biosignatures. Clinical Infectious Diseases, 0, , .	5.8	0
202	Point-of-care test for tuberculosis - a boon in diagnosis. Monaldi Archives for Chest Disease, 0, , .	0.6	2
203	Systematic review of diagnostic and prognostic host blood transcriptomic signatures of tuberculosis disease in people living with HIV. Gates Open Research, 0, 7, 27.	1.1	0
204	Field evaluation of a point-of-care triage test for active tuberculosis (TriageTB). BMC Infectious Diseases, 2023, 23, .	2.9	0
205	Characterizing the landscape of gene expression variance in humans. PLoS Genetics, 2023, 19, e1010833.	3.5	1
206	Identification of circulating monocytes as producers of tuberculosis disease biomarker C1q. Scientific Reports, 2023, 13, .	3.3	0
207	Research tests for the diagnosis of tuberculosis infection. Expert Review of Molecular Diagnostics, 2023, 23, 783-795.	3.1	5
209	Advancing tuberculosis management: the role of predictive, preventive, and personalized medicine. Frontiers in Microbiology, 0, 14, .	3.5	0
210	Alterations of lipid-related genes during anti-tuberculosis treatment: insights into host immune responses and potential transcriptional biomarkers. Frontiers in Immunology, 0, 14, .	4.8	0
211	Singleâ€Cell Sequencing Reveals Functional Alterations in Tuberculosis. Advanced Science, 2024, 11, .	11.2	0
212	Public health implications of the evolving understanding of tuberculosis natural history. Jammi, 2024, 8, 241-244.	0.5	0
213	Whole blood RNA signatures in tuberculosis patients receiving H56:IC31 vaccine as adjunctive therapy. Frontiers in Immunology, 0, 15, .	4.8	0

#	Article	IF	Citations
214	Large-scale analysis reveals splicing biomarkers for tuberculosis progression and prognosis. Computers in Biology and Medicine, 2024, 171, 108187.	7.0	0
215	Activin A levels are raised during human tuberculosis and blockade of the activin signaling axis influences murine responses to M. tuberculosis infection. MBio, 2024, 15, .	4.1	0
216	A Review Of Host-Specific Diagnostic And Surrogate Biomarkers In Children With Pulmonary Tuberculosis. Paediatric Respiratory Reviews, 2024, , .	1.8	0
217	C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay. Frontiers in Immunology, 0, 15, .	4.8	0